Prevention of esophageal strictures in a caustic burn model using halofuginone, an inhibitor of collagen type I synthesis

Laryngoscope

Volumn 115, Issue 9, 2005, Pages 1632-1635

  Arbell, Dan ^a   Udassin, Raphael ^a   Koplewitz, Benjamin Z ^a   Ohana, Meir ^a   Genina, Olga ^b   Pines, Mark ^b   Nagler, Arnon ^c  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b VOLCANI CENTER   (Israel)

^c SHEBA MEDICAL CENTER   (Israel)

Author keywords

Caustic injury; Esophageal stricture; Halofuginone

Indexed keywords

COLLAGEN TYPE 1; HALOFUGINONE; SODIUM HYDROXIDE; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CAUSTIC BURN; COLLAGEN SYNTHESIS; CONTROLLED STUDY; DRUG EFFECT; ESOPHAGUS INJURY; ESOPHAGUS MUSCLE; ESOPHAGUS STRICTURE; HISTOPATHOLOGY; MODEL; NONHUMAN; PRIORITY JOURNAL; RAT; SCAR FORMATION; SURVIVAL; THICKNESS; UPPER GASTROINTESTINAL TRACT; WOUND HEALING;

ANIMALS; BURNS, CHEMICAL; CAUSTICS; COLLAGEN TYPE I; ESOPHAGEAL STENOSIS; PIPERIDINES; PROTEIN SYNTHESIS INHIBITORS; QUINAZOLINES; QUINAZOLINONES; RATS; SODIUM HYDROXIDE; TRANSFORMING GROWTH FACTOR BETA; WOUND HEALING;

EID: 24944503009     PISSN: 0023852X     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mlg.0000176551.09051.f2     Document Type: Article

References (14)

1. Nunes AC, Romaozinho JM, Pontes JM, et al. Risk factors for stricture development after caustic ingestion. Hepatogastroenterology 2002;49:1563-1566.
2. Yeming W, Somme S, Chenren S, et al. Balloon catheter dilatation in children with congenital and acquired esophageal anomalies. J Pediatr Surg 2002;37:398-402.
3. Bingol-Kologlu M, Tanyel FC, Muftuoglu S, et al. The preventative effect of heparin on stricture formation after caustic esophageal burns. J Pediatr Surg 1999;34:291-294.
4. Liu AJ, Richardson MA. Effects of N-acetylcysteine on experimentally induced esophageal lye injury. Ann Otol Rhino Laryngol 1985;94:477-482.
5. Gehanno P, Guedon C. Inhibition of experimental esophageal lye strictures by penicillamine. Arch Otolaryngol 1981;07:145-147.
6. Cakmak M, Nayci A, Renda N, et al. The effect of corticosteroids and pentoxifylline in caustic esophageal burns. A prospective trial in rats. Int Surg 1997;82:371-375.
7. Gunel E, Caglayan F, Caglayan O, et al. Effect of antioxidant therapy on collagen synthesis in corrosive esophageal burns. Pediatr Surg Int 2002;8:24-27.
8. Nagler A, Rivkind AI, Raphael J, et al. Halofuginone, an inhibitor of collagen type I synthesis, prevents postoperative formation of abdominal adhesions. Ann Surg 1998;227:575-582.
9. Nagler A, Gofrit O, Ohana M, et al. The effect of halofuginone, an inhibitor of collagen type I synthesis, on urethral stricture formation: in vivo and in vitro study in a rat model. J Urol 1 2000;64:1776-1780.
10. Nagler A, Genina O, Lavelin I, et al. Halofuginone, an inhibitor of collagen type I synthesis, prevents postoperative adhesion formation in the rat uterine horn model. Am J Obstet Gynecol 1999;80:558-563.
11. Nagler A, Pines M, Vexler A, Gorodetsky R. HF specific inhibitor of collagen type I deposition does not affect wound strength in normal and irradiated mouse skin, (personal communication).
12. Abramovitch R, Dafni H, Neeman M, et al. Inhibition of neovascularization and tumor growth, and facilitation of wound repair, by Halofuginone, an inhibitor of collagen type I synthesis. Neoplasia 1999;1:1-9.
13. McGaha TL, Phelps RG, Spiera H, Bona C. Halofuginone, an inhibitor of type-I collagen synthesis and skin sclerosis, blocks transforming-growth-factor- beta-mediated Smad3 activation in fibroblasts. J Invest Dermatol 2002;118:461-470.
14. Pines M, Snyder D, Yarkoni S, Nagler A. Halofuginone to treat fibrosis in chronic graft-versus-host disease and scleroderma. Biol Blood Marrow Transplant 2003;9:417-425.